A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

NCT05198323 ↗

Phase 2 Recruiting 66 enrolled Lumosa Therapeutics Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase IIb clinical study to evaluate the safety and efficacy of single or multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).

Timeline

Start: 2022-08-11
Primary completion: 2026-03-31
Completion: 2026-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LT3001	Unknown	—	Intravenous

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Summary

Timeline

Drugs

Indications